CVR number 16155934
Industry 86.2100 General medical practice activities

LÆGEHUSET RÅDHUSGADE 9. AABENRAA ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Bankruptcy risk for industry  0.5% 0.5% 0.5% 0.5% 0.5%  
Bankruptcy risk  2.4% 1.8% 2.6% 3.7% 3.5%  
Credit score (0-100)  63 70 60 50 53  
Credit rating  BBB A BBB BBB BBB  
Credit limit (kDKK)  0.0 1.8 0.0 0.0 0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales  0 0 0 0 0  
Gross profit  334 433 271 248 268  
EBITDA  334 433 271 248 268  
EBIT  177 274 56.5 21.0 5.1  
Pre-tax profit (PTP)  144.2 161.6 -7.0 -35.1 -46.7  
Net earnings  112.4 126.0 -4.8 -26.4 -36.4  
Pre-tax profit without non-rec. items  144 162 -7.0 -35.1 -46.7  
 
See the entire income statement

Balance sheet (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Tangible assets total  4,525 5,702 5,716 5,864 6,066  
Shareholders equity total  3,662 3,788 3,783 3,757 3,720  
Interest-bearing liabilities  945 2,227 2,127 2,025 1,922  
Balance sheet total (assets)  4,820 6,175 6,098 6,108 6,212  
Net Debt  702 2,098 1,985 1,863 1,890  
 
See the entire balance sheet

Volume 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  334 433 271 248 268  
Gross profit growth  -20.0% 29.6% -37.3% -8.5% 8.2%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  4,820 6,175 6,098 6,108 6,212  
Balance sheet change%  -1.5% 28.1% -1.2% 0.2% 1.7%  
Added value  333.9 432.7 271.3 235.8 268.4  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  -178 1,018 -201 -78 -61  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  4.0 5.0 5.0 5.0 5.0  

Profitability 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  53.0% 63.3% 20.8% 8.5% 1.9%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  3.6% 5.0% 0.9% 0.4% 0.1%  
ROI %  3.7% 5.1% 0.9% 0.4% 0.1%  
ROE %  3.1% 3.4% -0.1% -0.7% -1.0%  

Solidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Equity ratio %  76.0% 61.3% 62.0% 61.5% 59.9%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  210.1% 484.9% 731.7% 750.7% 704.4%  
Gearing %  25.8% 58.8% 56.2% 53.9% 51.7%  
Net interest  0 0 0 0 0  
Financing costs %  3.0% 7.1% 2.9% 2.7% 2.7%  

Liquidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Quick Ratio  1.2 2.7 1.9 0.7 0.2  
Current Ratio  1.2 2.7 1.9 0.7 0.2  
Cash and cash equivalent  244.0 129.0 141.2 162.0 31.2  

Capital use efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  45.6 298.6 176.2 -109.6 -462.5  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0